Natural killer T cell activation inhibits hepatitis B virus replication in vivo

Kazuhiro Kakimi, Luca G. Guidotti, Yasuhiko Koezuka, Francis V. Chisari

Research output: Contribution to journalArticle

489 Citations (Scopus)

Abstract

We have previously reported that hepatitis B virus (HBV)-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T lymphocytes can inhibit HBV replication in the liver of HBV transgenic mice by secreting interferon (IFN)-γ when they recognize viral antigen. To determine whether an activated innate immune system can also inhibit HBV replication, in this study we activated natural killer T (NKT) cells in the liver of HBV transgenic mice by a single injection of α-galactosylceramide (α-GalCer), a glycolipid antigen presented to Vα14+NK1.1+ T cells by the nonclassical major histocompatibility complex class I-like molecule CD1d. Within 24 h of α-GalCer injection, IFN-γ and IFN-α/β were detected in the liver of HBV transgenic mice and HBV replication was abolished. Both of these events were temporally associated with the rapid disappearance of NKT cells from the liver, presumably reflecting activation-induced cell death, and by the recruitment of activated NK cells into the organ. In addition, prior antibody-mediated depletion of CD4+ and CD8+ T cells from the mice did not diminish the ability of α-GalCer to trigger the disappearance of HBV from the liver, indicating that conventional T cells were not downstream mediators of this effect. Finally, the antiviral effect of α-GalCer was inhibited in mice that are genetically deficient for either IFN-γ or the IFN-α/β receptor, indicating that most of the antiviral activity of α-GalCer is mediated by these cytokines. Based on these results, we conclude that α-GalCer inhibits HBV replication by directly activating NKT cells and by secondarily activating NK cells to secrete antiviral cytokines in the liver. In view of these findings, we suggest that, if activated, the innate immune response, like the adaptive immune response, has the potential to control viral replication during natural HBV infection. In addition, the data suggest that therapeutic activation of NKT cells may represent a new strategy for the treatment of chronic HBV infection.

Original languageEnglish
Pages (from-to)921-930
Number of pages10
JournalJournal of Experimental Medicine
Volume192
Issue number7
DOIs
Publication statusPublished - Oct 2 2000

Fingerprint

Natural Killer T-Cells
Virus Replication
Hepatitis B virus
Interferons
Liver
Transgenic Mice
Antiviral Agents
Virus Diseases
T-Lymphocytes
Natural Killer Cells
CD1d Antigen
Interferon Receptors
Murine hepatitis virus
Galactosylceramides
Cytokines
Injections
Viral Antigens
Glycolipids
Chronic Hepatitis B
Cytotoxic T-Lymphocytes

Keywords

  • Hepatitis B virus
  • Immunity
  • Liver
  • Natural killer T cells
  • Transgenic/knockout

ASJC Scopus subject areas

  • Immunology

Cite this

Natural killer T cell activation inhibits hepatitis B virus replication in vivo. / Kakimi, Kazuhiro; Guidotti, Luca G.; Koezuka, Yasuhiko; Chisari, Francis V.

In: Journal of Experimental Medicine, Vol. 192, No. 7, 02.10.2000, p. 921-930.

Research output: Contribution to journalArticle

Kakimi, Kazuhiro ; Guidotti, Luca G. ; Koezuka, Yasuhiko ; Chisari, Francis V. / Natural killer T cell activation inhibits hepatitis B virus replication in vivo. In: Journal of Experimental Medicine. 2000 ; Vol. 192, No. 7. pp. 921-930.
@article{dd7cbedc4d304775b36ea5013e82b497,
title = "Natural killer T cell activation inhibits hepatitis B virus replication in vivo",
abstract = "We have previously reported that hepatitis B virus (HBV)-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T lymphocytes can inhibit HBV replication in the liver of HBV transgenic mice by secreting interferon (IFN)-γ when they recognize viral antigen. To determine whether an activated innate immune system can also inhibit HBV replication, in this study we activated natural killer T (NKT) cells in the liver of HBV transgenic mice by a single injection of α-galactosylceramide (α-GalCer), a glycolipid antigen presented to Vα14+NK1.1+ T cells by the nonclassical major histocompatibility complex class I-like molecule CD1d. Within 24 h of α-GalCer injection, IFN-γ and IFN-α/β were detected in the liver of HBV transgenic mice and HBV replication was abolished. Both of these events were temporally associated with the rapid disappearance of NKT cells from the liver, presumably reflecting activation-induced cell death, and by the recruitment of activated NK cells into the organ. In addition, prior antibody-mediated depletion of CD4+ and CD8+ T cells from the mice did not diminish the ability of α-GalCer to trigger the disappearance of HBV from the liver, indicating that conventional T cells were not downstream mediators of this effect. Finally, the antiviral effect of α-GalCer was inhibited in mice that are genetically deficient for either IFN-γ or the IFN-α/β receptor, indicating that most of the antiviral activity of α-GalCer is mediated by these cytokines. Based on these results, we conclude that α-GalCer inhibits HBV replication by directly activating NKT cells and by secondarily activating NK cells to secrete antiviral cytokines in the liver. In view of these findings, we suggest that, if activated, the innate immune response, like the adaptive immune response, has the potential to control viral replication during natural HBV infection. In addition, the data suggest that therapeutic activation of NKT cells may represent a new strategy for the treatment of chronic HBV infection.",
keywords = "Hepatitis B virus, Immunity, Liver, Natural killer T cells, Transgenic/knockout",
author = "Kazuhiro Kakimi and Guidotti, {Luca G.} and Yasuhiko Koezuka and Chisari, {Francis V.}",
year = "2000",
month = "10",
day = "2",
doi = "10.1084/jem.192.7.921",
language = "English",
volume = "192",
pages = "921--930",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "7",

}

TY - JOUR

T1 - Natural killer T cell activation inhibits hepatitis B virus replication in vivo

AU - Kakimi, Kazuhiro

AU - Guidotti, Luca G.

AU - Koezuka, Yasuhiko

AU - Chisari, Francis V.

PY - 2000/10/2

Y1 - 2000/10/2

N2 - We have previously reported that hepatitis B virus (HBV)-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T lymphocytes can inhibit HBV replication in the liver of HBV transgenic mice by secreting interferon (IFN)-γ when they recognize viral antigen. To determine whether an activated innate immune system can also inhibit HBV replication, in this study we activated natural killer T (NKT) cells in the liver of HBV transgenic mice by a single injection of α-galactosylceramide (α-GalCer), a glycolipid antigen presented to Vα14+NK1.1+ T cells by the nonclassical major histocompatibility complex class I-like molecule CD1d. Within 24 h of α-GalCer injection, IFN-γ and IFN-α/β were detected in the liver of HBV transgenic mice and HBV replication was abolished. Both of these events were temporally associated with the rapid disappearance of NKT cells from the liver, presumably reflecting activation-induced cell death, and by the recruitment of activated NK cells into the organ. In addition, prior antibody-mediated depletion of CD4+ and CD8+ T cells from the mice did not diminish the ability of α-GalCer to trigger the disappearance of HBV from the liver, indicating that conventional T cells were not downstream mediators of this effect. Finally, the antiviral effect of α-GalCer was inhibited in mice that are genetically deficient for either IFN-γ or the IFN-α/β receptor, indicating that most of the antiviral activity of α-GalCer is mediated by these cytokines. Based on these results, we conclude that α-GalCer inhibits HBV replication by directly activating NKT cells and by secondarily activating NK cells to secrete antiviral cytokines in the liver. In view of these findings, we suggest that, if activated, the innate immune response, like the adaptive immune response, has the potential to control viral replication during natural HBV infection. In addition, the data suggest that therapeutic activation of NKT cells may represent a new strategy for the treatment of chronic HBV infection.

AB - We have previously reported that hepatitis B virus (HBV)-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T lymphocytes can inhibit HBV replication in the liver of HBV transgenic mice by secreting interferon (IFN)-γ when they recognize viral antigen. To determine whether an activated innate immune system can also inhibit HBV replication, in this study we activated natural killer T (NKT) cells in the liver of HBV transgenic mice by a single injection of α-galactosylceramide (α-GalCer), a glycolipid antigen presented to Vα14+NK1.1+ T cells by the nonclassical major histocompatibility complex class I-like molecule CD1d. Within 24 h of α-GalCer injection, IFN-γ and IFN-α/β were detected in the liver of HBV transgenic mice and HBV replication was abolished. Both of these events were temporally associated with the rapid disappearance of NKT cells from the liver, presumably reflecting activation-induced cell death, and by the recruitment of activated NK cells into the organ. In addition, prior antibody-mediated depletion of CD4+ and CD8+ T cells from the mice did not diminish the ability of α-GalCer to trigger the disappearance of HBV from the liver, indicating that conventional T cells were not downstream mediators of this effect. Finally, the antiviral effect of α-GalCer was inhibited in mice that are genetically deficient for either IFN-γ or the IFN-α/β receptor, indicating that most of the antiviral activity of α-GalCer is mediated by these cytokines. Based on these results, we conclude that α-GalCer inhibits HBV replication by directly activating NKT cells and by secondarily activating NK cells to secrete antiviral cytokines in the liver. In view of these findings, we suggest that, if activated, the innate immune response, like the adaptive immune response, has the potential to control viral replication during natural HBV infection. In addition, the data suggest that therapeutic activation of NKT cells may represent a new strategy for the treatment of chronic HBV infection.

KW - Hepatitis B virus

KW - Immunity

KW - Liver

KW - Natural killer T cells

KW - Transgenic/knockout

UR - http://www.scopus.com/inward/record.url?scp=0034596944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034596944&partnerID=8YFLogxK

U2 - 10.1084/jem.192.7.921

DO - 10.1084/jem.192.7.921

M3 - Article

C2 - 11015434

AN - SCOPUS:0034596944

VL - 192

SP - 921

EP - 930

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 7

ER -